Overview

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Objective of the low-dose transplant regimen must produce the following effects: 1. Suppression of the patient's immune system to prevent rejection of the donor cells; 2. Control of the lymphoma. The pretransplant regimen must suppress the lymphoma sufficiently to prevent marked progression of the tumor and allow time for the GVT effect to occur.
Phase:
N/A
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Alemtuzumab
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine